securities fraud

UniQure faces class action lawsuit over alleged FDA disclosure misrepresentations. Investors have until April 13, 2026 deadline to join litigation.

Law firm investigates CoreWeave for allegedly concealing data center construction delays. Stock fell $14B after December disclosure of months-behind Texas facility project.

BellRing Brands faces securities fraud investigation for allegedly misrepresenting 2025 sales growth, attributing gains to retail inventory buildup rather than organic demand. Stock fell 33%.

Law firm sues uniQure for allegedly misrepresenting gene therapy trial status and FDA approval timeline, causing stock to surge 250% then fall 49% after FDA reversal.

REGENXBIO faces securities lawsuit for allegedly misleading investors about RGX-111 gene therapy safety concerns. FDA imposed clinical hold after trial participant developed CNS tumor.

Schall Law Firm launches securities fraud class action against Varonis Systems for allegedly making false statements about SaaS customer conversion and revenue growth during 2025.

Agilon Health faces securities class action lawsuit alleging materially false 2026 financial guidance and misleading statements about risk mitigation. Investors from February-August 2025 may participate.

Schall Law Firm recruits lead plaintiffs for MCTA securities fraud class action lawsuit stemming from alleged undisclosed promotion scheme and SEC trading suspension.

Class action lawsuit filed against Klarna alleging IPO securities fraud over undisclosed financial risks and misleading statements about loss reserves.

BlackRock TCP Capital faces securities fraud lawsuit alleging false statements about investment valuations and overstated net asset value. Investors have until April 6, 2026 to join.

Law firm seeks lead plaintiffs for MCTA class action lawsuit over alleged undisclosed stock promotion scheme and social media fraud. Deadline: February 17, 2026.

Klarna faces securities lawsuit alleging it concealed loss reserve increases in its September 2025 IPO. Investors have until February 20 to join the class action.

GSI Technology faces securities investigation for allegedly making false claims about chip capabilities. Stock dropped 14.2% after reports showed products didn't perform as advertised.

Class action lawsuit filed against Fermi Inc. alleging material misrepresentations in October 2025 IPO regarding Project Matador demand and financial viability disclosures.

Class action lawsuit filed against Ardent Health for allegedly overstating Q3 2025 revenue and inflating full-year EBITDA guidance by $57.5 million due to accounting system failures.

Ultragenyx Pharmaceutical faces class action lawsuit for allegedly making false statements about setrusumab drug efficacy and safety, affecting investors who bought securities between August 2023 and December 2025.

F5 faces class action lawsuit alleging it misrepresented security capabilities and failed to disclose a major product breach affecting investors between October 2024-2025.

Bath & Body Works faces a class action lawsuit for allegedly making false statements about its growth strategy's effectiveness and failing to disclose poor results to investors.

Law firm sues Oracle for allegedly misleading investors about AI spending's near-term revenue potential. Stock fell 11% after earnings missed expectations.

Fermi Inc. faces securities fraud lawsuit over Project Matador disclosures, alleging misrepresentation of tenant commitments. Stock fell 33% after primary tenant withdrew funding in December 2025.